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Background
The HVTN 505 trial recruits men who have sex with men
who are HIV uninfected, between the ages of 18 and 45,
and meet behavioral criteria demonstrating that they are
at risk of HIV infection. Current attitudes of HIV vaccine
research were assessed to inform the development of
recruitment materials.
Methods
Focus groups were held in four cities, with participants
self-reported to be men who have sex with men between
the ages of 18–45. Participants were recruited through
Craig's list and community based organizations. Word
and theme association with HIV vaccine trials, as well as
motivators and barriers to trial participation, were
explored. In a second phase, 12 men at a Seattle coffee
shop were interviewed and asked to select among three
potential headlines for materials.
Results
Focus group participants identified altruism as the top
motivator to participation in HIV vaccine research, and
participants reported HOPE as the first word that came to
mind after hearing ''HIV Vaccine.'' Associating HOPE and
HIV vaccine research was an objective in development a
recruitment campaign. Several headlines were developed
and three selected for further testing. One-half (50%) of
interviewees in Seattle chose HOPE TAKES ACTION as the
preferred headline. The headline reflects the altruism that
drives participation for many people; copy focuses on the
key barrier to participation by stating that the vaccines
cannot cause HIV infection.
Materials include print ads/posters, palm cards, postcards,
web banner ads and a website http://www.HopeTakesAc
tion.org. All materials direct readers to the website, which
provides basic information about the study and a mecha-
nism to request contact from a local study site.
Conclusion
Materials build on the perception of an HIV vaccine as
hope, and address concerns that inhibit trial participation.
They further reflect the mood of the country in the early
years of the Obama administration.
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